Agoracom Blog Home

Posts Tagged ‘CSE’

« Older Entries
Newer Entries »

$KABN.ca North America Announces Non-Brokered Private Placement Financing for up to $2.0 Million $MOS.ca $MOGO.ca $CTZ.ca

Posted by AGORACOM-JC at 6:20 PM on Thursday, December 10th, 2020
kabn-square-new
  • Announced that it has received interest for up to $2 Million of units pursuant to a non-brokered financing, which will close prior to the unrelated, best efforts brokered private placement of units which the Company previously announced on December 7, 2020.
  • The gross proceeds of these unrelated offerings together will be up to $3.15 Million. The Units in each of the Brokered Offering and Non-Brokered Offering are being offered at $0.15 per Unit, with each Unit comprised of one common share of the Company and one Common Share purchase warrant
  • Each Warrant shall be exercisable to acquire one Common Share at an exercise price of $0.20 per Warrant Share for a period of 24 months from the applicable closing.

TORONTO, ON / December 10, 2020 / KABN Systems NA Holdings Corp. (CSE:KABN) (the “Company” or “KABN North America” or “KABN NA“), a Canadian Fintech company that specializes in continuous online identity verification, management and monetization in Canada and the U.S., is pleased to announce that it has received interest for up to $2 Million of units (“Units“) pursuant to a non-brokered financing (the “Non-Brokered Offering“), which will close prior to the unrelated, best efforts brokered private placement (“Brokered Offering“) of units which the Company previously announced on December 7, 2020. The gross proceeds of these unrelated offerings together will be up to $3.15 Million. The Units in each of the Brokered Offering and Non-Brokered Offering are being offered at $0.15 per Unit, with each Unit comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant (a “Warrant“). Each Warrant shall be exercisable to acquire one Common Share (a “Warrant Share“) at an exercise price of $0.20 per Warrant Share for a period of 24 months from the applicable closing.

The Brokered Offering is expected to close on or about December 29, 2020, or on such earlier date as agreed upon between the Company and Agent, and the Non-Brokered Offering is expected to close on or about December 21, 2020, or on such earlier date as the Company determines, and each is subject to certain conditions, including receipt of subscription agreements and payment of the subscription amounts by subscribers. The Units to be issued will have a hold period of four months and one day from the applicable closing.

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.

About KABN North America
KABN Systems NA Holdings Corp. through its wholly owned subsidiary KABN Systems North America Inc. focuses on the verification, management and monetization of digital identity, empowering users to control and benefit from the use of their online identity. KABN NA’s propriety technology suite includes 4 key products:

  • Liquid Avatar allows users to create high quality digital icons representing their online personas. These icons, in conjunction with KABN ID, allow users to manage and control their Self Sovereign Identity and to use Liquid Avatars to share verifiable credentials, including access, identity and designation credentials, and public and permission based private data when they want and with whom they want.
  • KABN ID is an Always On, biometric and blockchain based digital identity validation and verification platform allowing users to continuously and confidently prove themselves throughout the online community.
  • KABN Card is a Visa approved prepaid card program allowing users to manage both digital and fiat currencies and earn cashback and other loyalty incentives.
  • KABN KASH is a cashback, loyalty and engagement program that powers the KABN NA’s revenue ecosystem. KABN NA provides its products and services at no cost to consumers and generates revenues through permission-based partner programs.

For more information, please visit www.kabnnaholdco.com or www.kabnsystemsna.com

KABN Systems NA Holding Corp. is a publicly listed company listed on the Canadian Securities Exchange under the symbol “KABN.”

For further information, please contact:
David Lucatch
647-725-7742 Ext. 701
[email protected]

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities under the KABN Financing in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward-Looking Information and Statements
This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein includes statements regarding the anticipated proceeds of the Non-Brokered Offering and Brokered Offering, the closing date of each of the Non-Brokered Offering and Brokered Offering and statements that suggest that the Non-Brokered Offering and Brokered Offering will be completed and may include, but is not limited to, information concerning the ability of the Company to generate revenues, roll out new programs and to successfully achieve business objectives, including to accelerate the Company’s development, customer acquisition and business platform, and expectations for other economic, business, and/or competitive factors.

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

Tags: , , , , , , , , ,
Posted in All Recent Posts, KABN, KABN Systems NA Holdings Corp. | Comments Off on $KABN.ca North America Announces Non-Brokered Private Placement Financing for up to $2.0 Million $MOS.ca $MOGO.ca $CTZ.ca

Innocan Pharma $INNO.ca Completes Its Trademark Registration in the EU, UK and Switzerland $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 4:09 PM on Thursday, December 10th, 2020
Innocan-Blog
  • Announced the completion of the registration of its trademarks: Innocan Pharma, Relief & Go and SHIR in the EU, UK and Switzerland.
  • These trademarks represent Innocan’s OTC and derma cosmetic brand products that were recently launched in the German and UK markets.

Herzliya, Israel and Calgary, Alberta–(December 10, 2020) –  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan“), is pleased to announce the completion of the registration of its trademarks: Innocan Pharma, Relief & Go and SHIR in the EU, UK and Switzerland. These trademarks represent Innocan’s OTC and derma cosmetic brand products that were recently launched in the German and UK markets.

Figure 1

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6922/69990_4005126294fb3804_002full.jpg

“We are excited to have a Registered Trademark for our Brands in time to allow us to initiate the sales effort in the EU, UK and Switzerland,” says Iris Bincovich, Founder and CEO of Innocan, “This is another way that we have added value to the Company that will be recognized in 2021.”

www.facebook.com/Innocanpharma

https://www.instagram.com/theinnocanpharma/

About Innocan

The Company, through its wholly owned Israeli subsidiary, Innocan Pharma Ltd. (“Innocan Israel”), is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD“). Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Tags: , , , , , , , , ,
Posted in Featured, Innocan Pharma Corporation | Comments Off on Innocan Pharma $INNO.ca Completes Its Trademark Registration in the EU, UK and Switzerland $CGC.ca $APHA $OVAT.ca $KHRN.ca

VIDEO – Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Prepares To Scale Real-Time COVID-19 Air Detector With First Distribution Agreements and $500,000 From Canadian Government $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 4:02 PM on Thursday, December 10th, 2020
kontrol-logo

Kontrol Energy (KNR:CSE) (KNRLF:OTCQB) is the Google NEST of smart building technology, with the Blue Chip client base to prove it.  As such, when COVID-19 started shutting down buildings, arenas and complexes, their announcement the Receipt Of Positive Lab Results for Live COVID-19 Testing was taken very seriously by the investment community, with the stock smashing through to all-time highs and consolidating nicely in the $3.50 range.

Much of that consolidation came as a result of “impatient investors” who unrealistically demanded immediate and big sales agreements for the BioCloud unit, priced at $US 12,000 EACH.  But KNR CEO Paul Ghezzi and his team know that real success comes from building a real foundation – and they did that in a mind boggling 3 months.  We’ve been in the smallcap business long enough to know that pulling off the following in 3 months is damn near impossible, until now:

DISTRIBUTION – On December 1, 2020 KNR announced Entering into Exclusive Distribution Agreement with United Safety and Survivability Corporation for BioCloud Technology Distribution in North America, Australia and New Zealand. The exclusivity applies to the industries defined as buses, rail and locomotive, subways, ambulances, fire trucks, first responder and military vehicles, with applicable associated facilities in the geography of North America , Australia , and New Zealand . The exclusivity period is 12 months with a six month mutual renewal option and is based on 5,000 units of BioCloud per annum, on a best efforts basis, to retain exclusivity. Pricing will not be disclosed for industry competitive purposes. 

In addition, KNR has also entered into two non-exclusive BioCloud distribution agreements covering Ontario and Saskatchewan.

MORE GOVERNMENT FUNDING –  On December 3rd, 2020 the Company announced that it had received an additional $500,000 in research and development funding from the Canadian Federal Government.  This comes after a $50,000 grant earlier this year.  

PATENTS FILED  – On November 30, 2020 KNR announced the filing of 4 patents for the BioCloud technology with 3 patents filed in the USA and 1 patent in Canada .

MANUFACTURING –  KNR has engaged OES Inc. a local design and contract manufacturer in London, Ontario to produce the BioCloud units.  OES Inc. has a long and established history of assisting with the design and manufacturing of complex technology. Initial maximum capacity has been set at 10,000 units per month.

With all its ducks lined up and ready, CEO Paul Ghezzi says Kontrol is now well positioned for commercialization and believes 2021 is going to provide investors what they have long been waiting for.  Well, at least those investors that didn’t think 3 months was an unreasonable amount of time do all of this in.  Everybody else will just have to wait to see BioCloud in a building near them and wonder what could have been.

Watch or listen to this powerful interview with Kontrol Energy CEO, Paul Ghezzi.

Tags: , , , , , , , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Featured, Kontrol Energy Corp. | Comments Off on VIDEO – Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Prepares To Scale Real-Time COVID-19 Air Detector With First Distribution Agreements and $500,000 From Canadian Government $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

CLIENT FEATURE: Datametrex $DM.ca $DTMXF #AI / #Covid19 Test Kit Distributor With $7.6M In Revenue For The First 9 Months of 2020 $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 11:53 AM on Thursday, December 10th, 2020

Datametrex AI Limited (DM:TSXV) (D4G:FSE) (DTMXF: OTC) an AI and Machine learning company was well positioned with deep roots in South Korea to make the ultimate pivot to Covid-19 test kit distribution.  When the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.

Since then, the company has signed multiple multi-million dollar Covid-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.  This is in addition to lucrative AI contracts with various levels of government and enterprise level customers such as LOTTE Group, the fifth-largest conglomerate in Korea with annual revenues of approximately $60B USD.

REVENUE $CAD

  • Q1 + 62% To $809,000
  • Q2 + 419% To $1,954,000
  • Q3 + 188% To $4,862,325

TOTAL Q1/Q2/Q3

REVENUE   $7.6M vs $2.6M = +192%

GROSS PROFIT $2.3M vs $961K = +139%

Here’s the recent headlines:

  • Completion of the IDEaS program Component 1b Milestone 4 (December 9, 2020)
  • Recognized revenue of $7.6 million for first 9 months of 2020 (November 25, 2020)
  • Datametrex Expands Distribution of Film and Television Coronavirus Testing Across Canada (October 27, 2020)
  • Expands to Toronto Film Production Company for COVID-19 Testing Solutions (September 30, 2020)
  • $20M Supply Agreement With Major Worldwide Media & Entertainment Company for COVID-19 (September 24, 2020).
  • Received Third COVID-19 Order from TV Production Company (September 21, 2020)
  • Received  COVID-19 Test Kits Order for $1.6M From a Canadian Mining Company (September 3, 2020)

The demand for Covid testing is robust and well documented by the following:

  • U.S. television productions stalled in Vancouver by bottleneck in COVID-19 testing Read More

As tweeted by Air Canada on November 22, 2020:

Prior to the global pandemic, leaders embraced advanced analytics and AI, for good reason. According to a 2018 study by the McKinsey Global Institute, entitled: Notes from the AI frontier: Applications and value of deep learning, these capabilities are estimated to have the potential to create between approximately $9.5 trillion and $15.4 trillion in annual global economic value.

The company’s wholly owned subsidiary Nexalogy also played a key technology support role in the #SeeSay2020 campaign to fight voter intimidation in this past USA election. The company’s AI technology allowed for cyber filtration to identify voter intimidation for elections related research.

The company has also experienced robust demand for related services. Datametrex entered into a sales agreement with 7-Eleven Korea for Robotic Process Automation infrastructure (RPA) in order to automate certain business processes.

The global RPA market size is expected to reach $7.2 billion by 2025, rising at a market growth of 32.6% CAGR during the forecast period. RPA is the technology that enables anyone to configure computer software today, or a “robot” to replicate and incorporate the actions of a person working within digital systems to conduct a business process.

Hub On AGORACOM / Corporate Profile

Tags: , , , , , , , , , ,
Posted in AGORACOM Client Feature, All Recent Posts, Datametrex AI Limited, Featured | Comments Off on CLIENT FEATURE: Datametrex $DM.ca $DTMXF #AI / #Covid19 Test Kit Distributor With $7.6M In Revenue For The First 9 Months of 2020 $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Avicanna $AVCN.ca $AVCNF Launches Medical Cannabis Program with its RHO Phyto Formulary Nationwide in Colombia $TRUL.ca $ACB

Posted by AGORACOM-JC at 7:42 AM on Thursday, December 10th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Leveraging the successful launch of the Company’s RHO Phyto ™ branded advanced medical cannabis product line in Canada, the portfolio of preparations , including oil drops, sublingual sprays, capsules and topicals , are now available nationwide in Colombia through physician prescription under the Magisterial model
  • The medical program includes Avicanna’s 3 pillars aimed at setting the gold standard for medical cannabis in Colombia and other Latin America n markets , including Medical community education , Advanced pharmaceutical – grade cannabinoid preparations and a Comprehensive patient support program
  • Coinciding with the launch of the medical program, Avicanna is hosting its second Colombian symposium Magisterial Formulas: Advances in Cannabinoid Research, Product Offering and Patient Access

TORONTO, Dec. 10, 2020 — Avicanna Inc. (” Avicanna ” or the ” Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces the launch of its medical cannabis program in Colombia, under compound pharmacy legislation “Formulaciones Magistrales”, in which Avicanna will provide its standardized, industry-leading cannabinoid formulary to patients and the medical community. Additionally, this program includes the education and training of the medical community and a comprehensive patient support program.

Aras Azadian, CEO of Avicanna Inc., commented: “After 2 years of preparation, we are proud to be launching this complete program in a market that is very significant to us and to be doing so with a medical community that we have been working closely with for close to 3 years. We believe that this medical program will set the gold standard for advanced cannabinoid-based medicine in Colombia and will act as a proof of concept for planned expansions into other Latin American markets.”

The pharmaceutical cannabinoid preparations, which require physician prescription, will be commercialized through a range of business models including direct sales to patients, delivery to national pharmacies and delivery to third party medical institutions across Colombia. This comprehensive medical cannabis program is the first of its kind in Colombia to be educating and training third party health care practitioners on the efficacy of advanced cannabinoid-based medicine across various clinical indications and comorbidities and providing appropriate cannabinoid solutions. The target therapeutic areas include neurological disorders such as epilepsy, Parkinson’s disease, multiple sclerosis, psychiatric indications such as PTSD, anxiety, depression as well as chronic pain.

This first complete portfolio of advanced cannabinoid preparations comprises the same scientifically developed formulations as Avicanna’s Canadian RHO Phyto branded dosage forms including topicals, oil drops, sublingual sprays, and capsules in range of CBD only and CBD-THC ratios. The products are subjected to typical pharmaceutical drug development, including stability studies and preclinical analysis where they have demonstrated superior stability and bioavailability in comparison to basic MCT oil formulations. Avicanna continues to advance these formulations through real world evidence trials and further preclinical studies with leading Canadian institutions and clinicians. In addition to its R&D efforts, the Company continues to optimize its current formulas and expand its pipeline of products to include alternative delivery mechanisms. The active pharmaceutical ingredients for this program are sourced from Avicanna’s majority owned subsidiary Santa Marta Golden Hemp S.A.S., where the cannabinoids are extracted from organic and sustainably cultivated plants. The final preparation of these products is completed through Avicanna’s own Good Production Practices (GPP) certified pharmacy lab in Bogota through its wholly owned subsidiary Avicanna LATAM S.A.S. (“Avicanna LATAM”), which is believed to be the first of its kind to be certified for cannabinoid preparations. The education and patient support programs are also managed and operated by Avicanna’s medical team to ensure the services meet Avicanna’s quality standards and complete the full vertical integration.

“At Avicanna, our focus has always been on patients, and today, with the launch of our medical program, patients in Colombia will have access to therapeutic alternatives that may contribute to the control of their comorbidities, improving their quality of life and solving possible unmet medical needs altogether. With that, we have established ourselves as a significant contributor to the health system in Colombia, where we intend to also introduce novel pharmaceutical forms and provide optimal care,” stated Dr. Carlos Maldonado, Senior Vice President, Clinical Development at Avicanna LATAM.

Avicanna’s educational program includes health care practitioner (“HCP”) training packages, educational modules, certifications, medical symposia and real-world evidence trials. The goal of this educational program is to contribute to scientific progress through evidence generation and to equip HCPs to provide patients with optimal care. A timely component of the Company’s educational program, its upcoming event titled Magisterial Formulas: Advances in Cannabinoid Research, Product Offering and Patient Access ” on December 10, 2020 at 10am EST, will officially kick off the nation program.

To register for the symposium please visit https://www.bigmarker.com/avicanna-latam-s-a-s/Simposio-de-Avicanna-Colombia-Cannabis-Medicinal

For more information regarding the Magisterial Preparations contact [email protected] .

About Avicanna Inc.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all 2 developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected] .

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with resp ec t to the ability of the Company to provide the Colombian population with standardized and advanced medical solutions , the ability of the Company and Avicanna LATAM to manufacture its line of advanced cannabinoid formulations to service individual prescriptions issued by qualified medical professionals , the Company’s ability to set the standard in Colombia and other Latin America n countries by offering products with years of extensive research and development manufactured with world-class quality standards, the ability of the unique formulations to maintain the stability of the cannabinoids over the course of treatment , the ability of the Company to source the cannabinoids for the manufacture of the medical cannabis products from Santa Marta Golden Hemp S.A.S. , the ability of the product formulations to address specific medical conditions, and the ability of Santa Marta Golden Hemp S.A.S. to continue to cultivate cannabis . Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020 and final short form prospectus dated November 27, 2020 , filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Tags: , , , , , , , , , ,
Posted in All Recent Posts, Avicanna Inc., Featured | Comments Off on Avicanna $AVCN.ca $AVCNF Launches Medical Cannabis Program with its RHO Phyto Formulary Nationwide in Colombia $TRUL.ca $ACB

Hollister Biosciences $HOLL.ca $HSTRF 100% Owned Subsidiary Venom Extracts Achieves Final $40 Million Revenue Milestone $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 7:11 AM on Thursday, December 10th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • Announced that further to the news release dated March 30th , 2020, its 100% owned subsidiary, Venom Extracts has achieved its second of two revenue milestones in accordance with the terms of the definitive agreement that was entered in connection with the acquisition of Venom by the Company
  • On December 9th , 2020, Venom achieved the second and final revenue milestone by generating in excess of CDN $40,000,000 of revenue calculated from January 1 st , 2020.

VANCOUVER, BC , Dec. 10, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTCPK: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co .” or ” Hollister “) a diversified cannabis branding company with products in over 230 dispensaries throughout California , and over 80 dispensaries throughout Arizona , is pleased to announce that further to the news release dated March 30 th , 2020, its 100% owned subsidiary, Venom Extracts (” Venom “) has achieved its second of two revenue milestones in accordance with the terms of the definitive agreement that was entered in connection with the acquisition of Venom by the Company (the ” Transaction “).

On December 9 th , 2020, Venom achieved the second and final revenue milestone by generating in excess of CDN$40,000,000 of revenue calculated from January 1 st , 2020. Hollister also reports that Venom generated CDN$ 4.8 million in adjusted EBITDA over the same period.  As a result, the Company will issue 9,870,018 common shares (the ” Earn-Out Shares “) to certain former Venom shareholders at a deemed price of $0.20 per Earn-Out Share. The Earn-Out Shares will not be subject to any hold period under applicable securities laws.

On November 4 th the state of Arizona passed Prop 207 authorizing the Adult Use of Cannabis. Arizona is a mature, limited license medical market with 123 Operational Dispensaries as of 10/31/20, and 287,715 patients reported as of September 2020 . “The victory also puts Arizona on pace to create one of the biggest new marijuana markets in the country. The Arizona recreational market could generate as much as USD $375 million – $400 million in its first year and $700 million – $760 million by 2024, according to projections by Marijuana Business Daily.”

Venom Extracts is a leading concentrate brand in Arizona , accounting for between 25-30% of category sales. Venom has 8 sku’s with varying product forms including; Shatter, Crystals, Nectar Sauce, Sugar Wax, Live Resin, Diamond Sauce , THC-A, and Vape Cartridges.  Venom products can be found in over 80 retail locations including Arizona’s market leader; Harvest Health and Recreation (CSE:HARV, OTCMKTS: HRVSF), leading multi-state cannabis operator Curaleaf  (CSE:CURA, OTCMKTS: CURLF), MUV by Atlmed and other leading dispensaries.

“We are very proud of the Arizona team and their ability to achieve this final revenue milestone and market leadership position.  We look forward to continuing the growth of our Arizona platform as it transitions to an adult use market.” shared Carl Saling , CEO of Hollister .

None of the securities to be issued pursuant to the Transaction have been or will be registered under the U.S. Securities Act of 1933, as amended (the ” U.S. Securities Act “), or any state securities laws, and any securities issued pursuant to the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Rule 506(b) of Regulation D and/or Section 4(a)(2) of the U.S. Securities Act and applicable exemptions under state securities laws. In addition, the securities issued under an exemption from the registration requirements of the U.S. Securities Act will be “restricted securities” as defined under Rule 144(a)(3) of the U.S. Securities Act and will contain the appropriate restrictive legend as required under the U.S. Securities Act.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Non-IFRS Financial Measures: This news release makes reference to certain non – IFRS financial measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. These measures are provided as additional information to complement the IFRS financial measures by providing further metrics to understand the Company’s results of operations from management’s perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. We use non – IFRS financial measures, including segmented revenue and adjusted EBITDA, to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Tags: , , , , , , , , , , , ,
Posted in Featured, Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca $HSTRF 100% Owned Subsidiary Venom Extracts Achieves Final $40 Million Revenue Milestone $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

ImagineAR $IP.ca $IPNFF Announces Agreement with Indian Superstar Singer Ananya Birla $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 7:06 AM on Thursday, December 10th, 2020
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

Ananya Birla Leading ImagineAR Consumer & Business Launch in India

  • Announced a partnership agreement with Indian Superstar Singer Ananya Birla to spearhead the ImagineAR consumer launch in India.
  • With over 350 million streams of her songs on streaming platforms, Ananya’s fan base is growing exponentially.
  • She also is the only multi-platinum selling English singer in India , pioneering many firsts in the global music scene.

VANCOUVER , BC and ERIE, Pa. , Dec. 10, 2020 – ImagineAR (CSE: IP) (OTCQB: IPNFF) an Augmented Reality company that enables sports teams, entertainers, brands and businesses to instantly create their own global mobile phone AR campaigns, is excited  to announce a partnership agreement with Indian Superstar Singer Ananya Birla to spearhead the ImagineAR consumer launch in India.  With over 350 million streams of her songs on streaming platforms, Ananya’s fan base is growing exponentially. She also is the only multi-platinum selling English singer in India , pioneering many firsts in the global music scene.

ImagineAR Announces Agreement with Indian Superstar Singer Ananya Birla (CNW Group/ImagineAR)

Ananya Birla said “Technology plays a pivotal role in having one’s music reach a wider audience. I am excited to be partnering with a technology leader like ImagineAR to break new ground with technology in music. I want to thank Greg Thompson , my strategic manager and mentor, for playing such an integral role in this project.”

Greg Thompson , President of Maverick and Manager for Ananya Birla , “Ananya’s partnership with ImagineAR provides a great opportunity to continue to expand her global brand while bringing her relationship with her fans into an even greater level of connection”.

“Ananya is truly a role model for today’s women as a successful singer, entrepreneur and mental health advocate”, stated Alen Paul Silverrstieen CEO of ImagineAR, “We are proud and honored to be represented by Ananya as ImagineAR expands into the Indian consumer marketplace. We thank Mike Tunnicliffe , our ImagineAR Board of Director, for introducing our company to Greg Thompson of Maverick and Ananya.”

About Ananya Birla

“Her empowering spirit translates directly to her music” – Billboard

“An Indian born, London -bred badass who serves an inspiration to marginalized youth and women of all continents ” – Euphoria

“An integral part of her nation’s music history” – Schon

“One of the most striking artists on the interna tion a l pop scene ” – FabUK

“Ananya Birla’s ‘Fingerprint’ EP is a whole snack ” – Earmilk

“A woman to watch”- My Domaine

“She is ready to become a breakout artist worldwide” – Ones To Watch

“Ananya Birla is a name and sound to be remembered” – Play It By Ear

“A whirlwind of talent and ambition” – Rookie Mag

Ananya is a 26-year-old singer-songwriter from Mumbai , based between Mumbai and Los Angeles , where she is signed to Maverick Management.

The first homegrown artist to go Platinum with an English language track in India and that too multiple times, Ananya has hit over 350 million global streams.

Blazing her own path, and recently making history again as the first Indian artist to be played on Top 40 U.S. radio, “Everybody’s Lost” follows the release of Ananya’s first-ever U.S. single “Let There Be Love”. The single received immediate radio support from Radio Disney and SiriusXM Hits 1 (who also named her as a ‘1 To Watch’). Last year, Ananya released the infectious ‘Day Goes By’ with Jamaican-American hitmaker Sean Kingston , one of the first major collabs between US and Indian music artists. This followed multi-platinum selling hits, ‘Hold On’, ‘Meant To Be’, ‘Circles’, ‘Livin’ the Life’ (remixed by Afrojack), ‘Better’ and the release of her first EP ‘Fingerprint’ with UMG and Island Records, which included hit single ‘Blackout’ featuring Nigerian hip-hop stars Vector and WurlD.

The self-taught santoor and guitar player has been propelled from low-key gigs around London to performing at some of Asia’s biggest music events including Global Citizen, Oktoberfest and Sunburn, and opening for artists like Wiz Khalifa and Coldplay. Ananya has scaled the charts at home and appeared on major playlists and radio stations in the US, UK, Europe, Australia , the Middle East and SE Asia.

Listed as one of GQ’s Most Influential Young Indians and a Forbes Woman to Watch, Ananya is a strong believer in equality.

Ananya launched the Ananya Birla Foundation that aims to address mental health, education, humanitarian relief, climate change, equality and financial inclusion, related causes. The Foundation was kicked off with a COVID-19 relief project that involved providing menstruation kits, PPE kits and protective equipment to women and hospitals across Maharashtra. The Foundation also worked in providing essentials to migrant workers during the pandemic, and has just commenced a pioneering research project for mental health in rural India.

She also promotes female empowerment through her financial technology business Svatantra which serves women entrepreneurs in rural and semi-urban India grow their businesses and become financially independent. Svatantra means ‘freedom’ in Hindi and currently serves over a million women.

https://www.ananyabirla.com/

About ImagineAR

ImagineAR Inc. (CSE: IP) (OTC: IPNFF) is an augmented reality (AR) platform, ImagineARStudio.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies.

For more information or to explore working with ImagineAR, please email [email protected] , or visit www.imagineAR.com .

All trademarks of the property of respective owners.

ON BEHALF OF THE BOARD

Alen Paul Silverrstieen
 President & CEO
 (818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

We encourage you to do your own due diligence and ask your broker if Imagine AR Inc. (cse: IP) is suitable for your particular investment portfolio*.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward- looking information is based on certain key expectations and assumptions made by ImagineAR’s management. Although Imagine AR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Imagine AR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and Imagine AR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Tags: , , , , , , , , , , ,
Posted in Imagine AR | Comments Off on ImagineAR $IP.ca $IPNFF Announces Agreement with Indian Superstar Singer Ananya Birla $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

VIDEO – FansUnite $FANS.ca $FUNFF Malta Gaming Licences Open Up Europe + 150 Jurisdictions. U.K. Is Next and Sights Set On Canada $SCR.ca $BRAG.ca $TNA.ca $FDM.ca $JJ.ca

Posted by AGORACOM-JC at 5:02 PM on Wednesday, December 9th, 2020

The global online gambling market could potentially hit $1 TRILLION by the end of this decade. That isn’t a typo and the reasons are pretty clear – more jurisdictions are legalizing online gambling to get their hands on the tax revenue and the remaining 40% of people on the planet without internet access are going to get it.  

Until recently, however, small-cap investors did not have a company that could provide them ground floor exposure to this massive market and its growth over the next 10 years.  The industry was dominated by the big traditional gambling companies, who focus heavily on old fashioned gambling. 

That all changes with FansUnite, the small cap iGaming super company that goes beyond simple gambling and attacks both sides of the iGaming market by offering both B2C and B2B gambling platforms.  

More than just lip service, FANS recently announced a record October, with the highest increase in monthly revenue and gross margin in the Company’s history.

MALTA LICENCES DONE …. U.K. AND CANADA ARE NEXT

If that was all FANS accomplished in Q4, investors would be really happy  … but watch this interview to hear just how big of an impact the Company’s 2 new Malta gaming licenses are to the future expansion of the Company.  The business development doors are now wide open for Europe and 150 jurisdictions.  Moreover, with the U.K. having its own gaming licenses, FANS is already in pursuit and is feeling confident given its success with Malta. 

If that wasn’t enough, FANS is also strongly positioned for a proposed change to Canadian gambling laws that could become a massive opportunity for the Canadian gambling and gaming company.  

If you are looking for a disruptive technology company that is well positioned to carve out its share of the massive online gambling world, then you need to watch or listen to this interview with FANS CEO, Scott Burton.

Tags: , , , , , , , , , ,
Posted in AGORACOM Via Satellite, FansUnite Entertainment Inc., Featured | Comments Off on VIDEO – FansUnite $FANS.ca $FUNFF Malta Gaming Licences Open Up Europe + 150 Jurisdictions. U.K. Is Next and Sights Set On Canada $SCR.ca $BRAG.ca $TNA.ca $FDM.ca $JJ.ca

AGORACOM Small Cap 60: Binovi Technologies $VISN.ca $BNVIF A Step Ahead In Correcting Vision $EYPT $KALA $PTON $WELL.ca $DOC.ca $DOCRF

Posted by AGORACOM-JC at 12:44 PM on Wednesday, December 9th, 2020

Executive Chairman, Terry Booth describes Binovi Technologies (VISN:TSXV) (BNVIF:OTCQB) as “A step ahead in correcting vision. Mr Booth points out that 20/20 vision does not guarantee great binocular vision. He continues to mention that utilizing vision therapy is often highly effective in correcting any deficiencies in Binocular vision. This therapy can be highly advantageous for children especially in the early elementary years.

Hub On AGORACOM / Corporate Profile

Tags: , , , , , ,
Posted in AGORACOM Small Cap 60, All Recent Posts, Binovi Technologies Corp. | Comments Off on AGORACOM Small Cap 60: Binovi Technologies $VISN.ca $BNVIF A Step Ahead In Correcting Vision $EYPT $KALA $PTON $WELL.ca $DOC.ca $DOCRF

Datametrex $DM.ca $DTMXF Completes IDEaS Milestone 4 and Launches Nexalogy “SMART” $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 9:43 AM on Wednesday, December 9th, 2020
Webinar logo
  • Announced the completion of the IDEaS program Component 1b Milestone 4, as well as the launch of Nexalogy’s Social Media Automated Reporting Technologies (“SMART”)
  • The Company will receive approximately $218,000.00 CAD for the Component 1b Milestone 4. Combined, the total for all Milestones in Component 1b is approximately $945,000.00 CAD

Toronto, Ontario–(December 9, 2020) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC: DTMXF) (the “Company” or “Datametrex”) is pleased to announce the completion of the IDEaS program Component 1b Milestone 4, as well as the launch of Nexalogy’s Social Media Automated Reporting Technologies (“SMART”). The Company will receive approximately $218,000.00 CAD for the Component 1b Milestone 4. Combined, the total for all Milestones in Component 1b is approximately $945,000.00 CAD.

As previously announced, Nexalogy’s SMART is an advanced proprietary AI technology. SMART minimizes human involvement in data analysis and reporting. It significantly decreases the time required for integration and interpretation of large data sets and report production. Nexalogy has completed the IDEaS Component 1b Milestone 4, and as a result, SMART has been tested internally with several existing clients. It is expected to be fully available in Q4 of 2020.

AI reporting on social media and other forms of unstructured text is increasingly important. Global developments in the information landscape, as well as the increased importance of telework with the COVID-19 pandemic, have both contributed to the need for strategic reporting of data from these platforms. In terms of automation, SMART helps to reduce the time involved in the analysis and management of the data deluge. In terms of objectivity, SMART helps to reduce human bias and error when dealing with big data. SMART increases efficiency for an extra layer of defence against terrorism, pandemics, and overall crises, as well as providing clients with an edge to be ahead of social trends, competitors, and new audiences.

“We are very happy to have successfully completed the IDEaS Component 1B Milestone 4 and the launch of SMART,” said Marshall Gunter, President and CEO of the Datametrex AI Limited. “Datametrex has put significant effort into the R&D behind SMART, which is a major goal of the IDEaS program. We are confident that our cutting edge technology will significantly benefit our clients. We look forward to deploying this technology in new verticals.”

About SMART (Social Media Auto-Reporting Technologies)

SMART reduces the time needed to interpret and integrate large sets of data by offering powerful automated analyses. Rather than replacing the human analyst, he/she sets the parameters of the data collection via keywords and other social media information (e.g., usernames and links). This allows for the identification of data needing extraction and analysis. SMART extracts the relevant data and produces automated reports, thus allowing clients to work with a more manageable information set. SMART allows an analyst to deal with hundreds of thousands of social media documents in minutes rather than hours or days.

Analysts can specify filters on the data to get automatic reports on subsets of the data focusing on specific times, entities, social media users, or topics. The resulting reports are delivered either as PDFs, DOCs, or via API for further processing. The report generation can be scheduled to occur either at regular intervals or to be triggered by specific changes in the conversation (e.g., a sudden increase in volume or an increase in mentions of a particular named entity).

Lastly, SMART analysis helps the user to easily access the required information and helps to detect patterns that currently go unrecognized. This is needed in both the context of the ‘short game’ of crisis reporting and the ‘long game’ of identifying narratives, as discussed within the BEND (Build Engage Neutralize Distract) framework.

For more information about the technology, please reach out to us.

About IDEaS

IDEaS, an initiative by the Canadian Government, supports the development of solutions from their conceptual stage, through prototype testing and capability development. The program includes several elements that promote collaboration between innovators, provide developmental resources and provide opportunities to interact with DND’s science and military members. In this way all innovators are on an even playing field to solve specific defence and security challenges. For more info about the program, see here: https://www.canada.ca/en/department-national-defence/programs/defence-ideas.html

About Datametrex

Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Tags: , , , , , , , ,
Posted in Datametrex AI Limited | Comments Off on Datametrex $DM.ca $DTMXF Completes IDEaS Milestone 4 and Launches Nexalogy “SMART” $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

« Older Entries
Newer Entries »